eligibility_summary
Adults ≥18 with measurable B‑cell lymphomas: CD19+ PTLD, rel/ref CD19+ B‑NHL (excl WM/MZL) with ≥1 prior and no better option, CD19+ DLBCL/FL/MCL relapsing ≥30 d after CAR T/allo‑Tx, or rel/ref CD19‑ B‑NHL with ≥1 prior and no better option. ECOG 0–2, adequate counts/renal/hepatic, contraception/pregnancy testing. Exclude prior/hypersensitivity to loncastuximab, active 2nd cancer, HBV/HCV, uncontrolled GVHD, CNS disease, major comorbidity, significant effusion, recent therapy/other trials/live vaccines.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm study of loncastuximab tesirine (Zynlonta, ADCT-402), a monoclonal antibody–drug conjugate (ADC). Drug/intervention: anti-CD19 IgG mAb linked to tesirine, a pyrrolobenzodiazepine (PBD) dimer cytotoxic payload, given IV q21d. Mechanism: mAb binds CD19 on malignant B cells, is internalized, and releases tesirine to create DNA interstrand crosslinks, triggering DNA damage response, cell-cycle arrest, and apoptosis. Targets: CD19-expressing B cells in relapsed/refractory B-cell malignancies (DLBCL, FL, MCL, PTLD), including post–CAR T or allogeneic transplant, a cohort also explores activity in CD19-low/negative B-NHL. Key pathways: CD19 antigen on B cells, downstream DNA damage/repair pathways (double-strand break response) leading to tumor cell death.